Skip to main content
Top
Published in: World Journal of Surgery 2/2018

01-02-2018 | Original Scientific Report

Long-Term Outcome After Surgery for Medullary Thyroid Carcinoma: A Single-Center Experience

Authors: Francesca Torresan, Elisabetta Cavedon, Caterina Mian, Maurizio Iacobone

Published in: World Journal of Surgery | Issue 2/2018

Login to get access

Abstract

Background

Medullary thyroid carcinoma (MTC) is a rare C cells-derived tumor, with a hardly predictable long-term prognosis. This study was aimed to evaluate the predictive factors of cure and survival after surgery for MTC in a monocentric series.

Methods

A retrospective analysis of the long-term outcomes was assessed in 255 MTC patients operated between 1980 and 2015 at Padua University hospital.

Results

Sporadic MTC occurred in 65.1% and hereditary MTC in 34.9% of patients. At a median follow-up of 93 months (range 7–430), the cure rate was 56.8%. The overall 10-year survival was 84.4%, and MTC-related death rate was 15.3%. Patients who died because of MTC had a median age of 61 years (range 21–84) and were at stages III–IV in all cases; deaths occurred in 18% of sporadic MTC, 6% of MEN2a and 66.7% of MEN2b patients. None of the patients at stages I–II died because of the disease, but 17.7% had persistent/recurrent disease. Based on univariate analysis, age, gender, genetic variant, extent and year of surgery, tumor size, lymph-nodal metastases and tumor stage significantly affected cure and survival rates. At multivariate analysis, only patient- and tumor-related features (age, lymph-nodal status and stage) remained significant independent prognostic factors.

Conclusions

Radical surgery is the only chance of definitive cure in MTC, but it is possible only at early stage; in advanced stages, even extensive surgery could not grant cure and prolonged survival. Stage, nodal metastases and age remain the main predictive factors for cure and survival.
Literature
1.
go back to reference Pacini F, Castagna MG, Cipri C et al (2015) Medullary thyroid carcinoma. Clin Oncol 22:475–485CrossRef Pacini F, Castagna MG, Cipri C et al (2015) Medullary thyroid carcinoma. Clin Oncol 22:475–485CrossRef
2.
go back to reference Wells SA, Asa SL, Dralle H et al (2015) Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid 25:567–610CrossRefPubMedPubMedCentral Wells SA, Asa SL, Dralle H et al (2015) Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid 25:567–610CrossRefPubMedPubMedCentral
3.
go back to reference Kebebew E, Greenspan FS, Clark OH et al (2005) Extent of disease and practice patterns for medullary thyroid cancer. J Am Coll Surg 200:890–896CrossRefPubMed Kebebew E, Greenspan FS, Clark OH et al (2005) Extent of disease and practice patterns for medullary thyroid cancer. J Am Coll Surg 200:890–896CrossRefPubMed
4.
go back to reference Modigliani E, Cohen R, Campos JM et al (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol (Oxf) 48:265–273CrossRef Modigliani E, Cohen R, Campos JM et al (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol (Oxf) 48:265–273CrossRef
5.
go back to reference Dottorini ME, Assi A, Sironi M et al (1996) Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 77:1556–1565CrossRefPubMed Dottorini ME, Assi A, Sironi M et al (1996) Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 77:1556–1565CrossRefPubMed
6.
go back to reference Raue F, Kotzerke J, Reinwein D et al (1993) Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Investig 71:7–12CrossRefPubMed Raue F, Kotzerke J, Reinwein D et al (1993) Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Investig 71:7–12CrossRefPubMed
7.
go back to reference Roman S, Lin R, Sosa JA (2006) Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107:2134–2142CrossRefPubMed Roman S, Lin R, Sosa JA (2006) Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107:2134–2142CrossRefPubMed
8.
go back to reference Siironen P, Hagström J, Mäenpää HO et al (2016) Lymph node metastases and elevated postoperative calcitonin: predictors of poor survival in medullary thyroid carcinoma. Acta Oncol 55:357–364CrossRefPubMed Siironen P, Hagström J, Mäenpää HO et al (2016) Lymph node metastases and elevated postoperative calcitonin: predictors of poor survival in medullary thyroid carcinoma. Acta Oncol 55:357–364CrossRefPubMed
9.
go back to reference AJCC (2017) AJCC cancer staging manuals, 8th edn. Springer, Berlin, pp 52–53 AJCC (2017) AJCC cancer staging manuals, 8th edn. Springer, Berlin, pp 52–53
10.
go back to reference Leboulleux S, Baudin E, Travagli JP et al (2004) Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 61:299–310CrossRef Leboulleux S, Baudin E, Travagli JP et al (2004) Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 61:299–310CrossRef
11.
go back to reference Machens A, Dralle H (2016) Surgical cure rates of sporadic medullary thyroid cancer in the era of calcitonin screening. Eur J Endocrinol 175:219–228CrossRefPubMed Machens A, Dralle H (2016) Surgical cure rates of sporadic medullary thyroid cancer in the era of calcitonin screening. Eur J Endocrinol 175:219–228CrossRefPubMed
13.
go back to reference De Groot JWB, Plukker JTM, Wolffenbuttel BHR et al (2006) Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol (Oxf) 65:729–736CrossRef De Groot JWB, Plukker JTM, Wolffenbuttel BHR et al (2006) Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol (Oxf) 65:729–736CrossRef
14.
15.
go back to reference Cupisti K, Wolf A, Raffel A et al (2007) Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution’s experience over 20 years. Ann Surg 246:815–821CrossRefPubMed Cupisti K, Wolf A, Raffel A et al (2007) Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution’s experience over 20 years. Ann Surg 246:815–821CrossRefPubMed
16.
go back to reference Abraham DT, Low T-H, Messina M et al (2011) Medullary thyroid carcinoma: long-term outcomes of surgical treatment. Ann Surg Oncol 18:219–225CrossRefPubMed Abraham DT, Low T-H, Messina M et al (2011) Medullary thyroid carcinoma: long-term outcomes of surgical treatment. Ann Surg Oncol 18:219–225CrossRefPubMed
17.
go back to reference Rendl G, Manzl M, Hitzl W et al (2008) Long-term prognosis of medullary thyroid carcinoma. Clin Endocrinol (Oxf) 69:497–505CrossRef Rendl G, Manzl M, Hitzl W et al (2008) Long-term prognosis of medullary thyroid carcinoma. Clin Endocrinol (Oxf) 69:497–505CrossRef
18.
go back to reference Kebebew E, Ituarte PHG, Siperstein AE et al (2000) Medullary thyroid carcinoma clinical characteristics, treatment, prognostic factors and a comparison of staging systems. Cancer 88:1139–1148CrossRefPubMed Kebebew E, Ituarte PHG, Siperstein AE et al (2000) Medullary thyroid carcinoma clinical characteristics, treatment, prognostic factors and a comparison of staging systems. Cancer 88:1139–1148CrossRefPubMed
19.
go back to reference Mirallié E, Iacobone M, Sebag F et al (2004) Results of surgical treatment of sporadic medullary thyroid carcinoma following routine measurement of serum calcitonin. Eur J Surg Oncol 30:790–795CrossRefPubMed Mirallié E, Iacobone M, Sebag F et al (2004) Results of surgical treatment of sporadic medullary thyroid carcinoma following routine measurement of serum calcitonin. Eur J Surg Oncol 30:790–795CrossRefPubMed
20.
go back to reference Brauckhoff M, Machens A, Lorenz K et al (2014) Surgical curability of medullary thyroid cancer in multiple endocrine neoplasia 2B. Ann Surg 259:800–806CrossRefPubMed Brauckhoff M, Machens A, Lorenz K et al (2014) Surgical curability of medullary thyroid cancer in multiple endocrine neoplasia 2B. Ann Surg 259:800–806CrossRefPubMed
21.
go back to reference Pelizzo MR, Torresan F, Nacamulli D et al (2015) Early, prophylactic thyroidectomy in hereditary medullary thyroid carcinoma: a 26-year monoinstitutional experience. Am J Clin Oncol 38:508–513CrossRefPubMed Pelizzo MR, Torresan F, Nacamulli D et al (2015) Early, prophylactic thyroidectomy in hereditary medullary thyroid carcinoma: a 26-year monoinstitutional experience. Am J Clin Oncol 38:508–513CrossRefPubMed
22.
go back to reference Elisei R, Cosci B, Romei C et al (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93:682–687CrossRefPubMed Elisei R, Cosci B, Romei C et al (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93:682–687CrossRefPubMed
23.
go back to reference Mian C, Pennelli G, Barollo S et al (2011) Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur J Endocrinol 164:971–976CrossRefPubMed Mian C, Pennelli G, Barollo S et al (2011) Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur J Endocrinol 164:971–976CrossRefPubMed
24.
go back to reference Romei C, Ugolini C, Cosci B et al (2012) Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer. Thyroid 22:476–481CrossRefPubMed Romei C, Ugolini C, Cosci B et al (2012) Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer. Thyroid 22:476–481CrossRefPubMed
25.
go back to reference Machens A, Dralle H (2010) Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 95:2655–2663CrossRefPubMed Machens A, Dralle H (2010) Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 95:2655–2663CrossRefPubMed
27.
go back to reference Machens A, Hauptmann S, Dralle H (2008) Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surg 95:586–591CrossRefPubMed Machens A, Hauptmann S, Dralle H (2008) Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surg 95:586–591CrossRefPubMed
28.
go back to reference Franc S, Niccoli-Sire P, Cohen R et al (2001) Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin Endocrinol (Oxf) 55:403–409CrossRef Franc S, Niccoli-Sire P, Cohen R et al (2001) Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin Endocrinol (Oxf) 55:403–409CrossRef
29.
go back to reference Tamagnini P, Iacobone M, Sebag F, Marcy M, De Micco C, Henry JF (2005) Lymph node involvement in macroscopic medullary thyroid carcinoma. Br J Surg 92(4):449–453CrossRefPubMed Tamagnini P, Iacobone M, Sebag F, Marcy M, De Micco C, Henry JF (2005) Lymph node involvement in macroscopic medullary thyroid carcinoma. Br J Surg 92(4):449–453CrossRefPubMed
30.
go back to reference Machens A, Dralle H (2013) Prognostic impact of N staging in 715 medullary thyroid cancer patients: proposal for a revised staging system. Ann Surg 257:323–329CrossRefPubMed Machens A, Dralle H (2013) Prognostic impact of N staging in 715 medullary thyroid cancer patients: proposal for a revised staging system. Ann Surg 257:323–329CrossRefPubMed
31.
go back to reference Pacini F, Schlumberger M, Dralle H et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803CrossRefPubMed Pacini F, Schlumberger M, Dralle H et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803CrossRefPubMed
32.
go back to reference Elisei R, Bottici V, Luchetti F et al (2004) Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 89:163–168CrossRefPubMed Elisei R, Bottici V, Luchetti F et al (2004) Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 89:163–168CrossRefPubMed
33.
go back to reference Costante G, Meringolo D, Durante C et al (2007) Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 92:450–455CrossRefPubMed Costante G, Meringolo D, Durante C et al (2007) Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 92:450–455CrossRefPubMed
Metadata
Title
Long-Term Outcome After Surgery for Medullary Thyroid Carcinoma: A Single-Center Experience
Authors
Francesca Torresan
Elisabetta Cavedon
Caterina Mian
Maurizio Iacobone
Publication date
01-02-2018
Publisher
Springer International Publishing
Published in
World Journal of Surgery / Issue 2/2018
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-017-4321-z

Other articles of this Issue 2/2018

World Journal of Surgery 2/2018 Go to the issue